MaaT034 / MaaT Pharma - LARVOL DELTA

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice (SITC 2025) - "MaaT034 was able to potentiate anti-PD1 mediated antitumoral activity in tumor-bearing germ-free mice. MaaT034 could offer a promising therapeutic benefit for the treatment of solid tumors in combination with ICI therapy."

IO biomarker • Preclinical • Oncology • Solid Tumor

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 (Businesswire) - "MaaT034 optimizes anti-PD1 mediated activity in tumor-bearing, germ-free mice. While anti-PD1 alone reduced tumor growth by 10%, the combination of anti-PD1 and MaaT034 resulted in a 83.7% tumor growth reduction (compared to a 24.2% reduction when using a single strain of Akkermansia muciniphila bacteria)."

Preclinical • Solid Tumor

MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 (Businesswire) - "Metagenomic analysis shows that MaaT034 reproduces the microbial functions of MaaT013...MaaT034 improves DC-mediated T cell activation and potentiates anti-tumor effects mediated by anti-PD-1 checkpoint blockade in vitro....70% of MaaT034 microbial species engraft in mice, ensuring an enduring presence of beneficial bacteria in the gut environment....MaaT034 optimizes anti-PD1 mediated activity in tumor-bearing, germ-free mice. While anti-PD1 alone reduced tumor growth by 10%, the combination of anti-PD1 and MaaT034 resulted in a 83.7% tumor growth reduction (compared to a 24.2% reduction when using a single strain of Akkermansia muciniphila1 bacteria)."

Preclinical • Solid Tumor

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, is capable to safely colonize the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and to stimulate immunity (AACR 2025) - "Altogether, these findings underscore MaaT034's potential to safely colonize the gastro-intestinal tract of mice and to produce key metabolites allowing to restore a healthy gut physiology and to stimulate both local and systemic immunity. As such, MaaT034 could offer a promising therapeutic benefit for the treatment of solid tumors in combination with ICI therapy."

IO biomarker • Preclinical • Oncology • Solid Tumor

Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors (SITC 2024) - "Finally, we performed an MLR-killing assay to evaluate the capability of MaaT034 to induce DC-mediated CD8+ T cell activation and subsequent killing of cancer cells. Conclusions Altogether, these findings underscore MaaT034's potential to produce metabolites that restore gut barrier integrity and stimulate immune cell responses to ICI therapy, which could offer a promising therapeutic benefit for the treatment of solid tumors."

Checkpoint inhibition • Combination therapy • IO biomarker • Oncology • Solid Tumor • CD8 • IFNG

MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update (Businesswire) - "MaaT013:...In March 2024, the Company informed on the completion of patient recruitment for the Phase 2a randomized clinical trial (NCT04988841) (PICASSO)....A total of 70 patients have been enrolled since April 2022.....Data readout is expected in Q4 2024/Q1 2025....MaaT034:...Clinical activities for MaaT034 are now expected to begin in 2026 and not 2025, as previously announced."

Clinical • P2a data • Trial status • Melanoma

Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors (AACR 2024) - "Altogether, these results highlight the potential of MaaT034 to produce metabolites involved in the restoration of gut barrier integrity and stimulation of immune cell response to ICI therapy, with potential benefit for solid tumors treatment."

Checkpoint inhibition • IO biomarker • Oncology • Solid Tumor • GZMB • IFNG • IL2RA

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies (Businesswire) - "MaaT Pharma...presented new in vitro data characterizing the metabolites produced by MaaT034 and their impact on immune modulation at the American Association for Cancer Research (AACR) Annual Meeting 2024....The first-in-human study is expected to be initiated in 2025....The results demonstrate that MaaT034 produced key metabolites, recognized as promoting gut barrier restoration and modulating immune responses, such as Short-Chain Fatty Acids (SCFA), secondary bile acids, and tryptophan derivatives. These findings support the role of MaaT034 in gut barrier repair and in T cell reactivation either in combination with Nivolumab (anti-PD1) or with Atezolizumab (anti-PD-L1)."

New trial • Preclinical • Solid Tumor

MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies (Businesswire) - "MaaT Pharma...will present new in vitro data at the American Association for Cancer Research (AACR) Annual Meeting 2024....MaaT034, a ground-breaking full ecosystem synthetic microbiota product, is the first candidate coming​ from the​ Company’s MET-C platform. Produced using a co-culturing technology and for large scale manufacturing, MaaT034 is being developed to improve responses to immunotherapy for patients with solid tumors in combination with an ICI (Immune Checkpoint Inhibitors) treatment. The first-in-human study is planned for 2025, with clinical batches currently being produced in 2024....Poster will present characterization of metabolites produced by MaaT034 and its immunomodulatory effects on host cells."

New trial • Preclinical • Solid Tumor

MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies (Businesswire) - "MaaT Pharma...announced today the details of two poster presentations at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting....Presentations will include in vitro results for its new Artificial Intelligence (AI)-generated lead product, MaaT034, designed to improve responses to immunotherapy for patients with solid tumors....The first-in-human testing is planned for 2025, with the first clinical batches to be produced in 2024....Key findings for MaaT034: (i) replicates, at large industrial scale, the richness and diversity of healthy native-based microbiome ecosystems; (ii) restores the integrity of a damaged gut barrier; (iii) activates AhR1 pathway involved in gut homeostasis; (iv) stimulates both myeloid and lymphoid immune cells."

Commercial • New trial • Preclinical • Solid Tumor

MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update (Businesswire) - "MaaT034 is the first member of the MaaT03X co-culture family from the MET-C platform. First in human is scheduled for 2025, with the manufacture of the first clinical batch in 2024. As a post period event, the Company announces that two posters have been accepted for the 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC), Nov 1-5, 2023 in San Diego, CA USA."

Commercial • New trial • Preclinical • Solid Tumor